explore -WSS

explore

author：explore 2025-10-02 22:24:01 - browse：7467

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

entertainment

WSS

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

What will save rural psychiatry services? Higher Medicaid payments

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

The Pandemic Treaty must support building strong health systems

iTeos Therapeutics debuts first data on TIGIT

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

entertainment

explore

focus

As demand for Covid shots wanes, Moderna seeks its next success

With trial win, GSK could get blood cancer drug back on market

How to save PrEP access — and even expand it

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ionis drug prevents swelling attacks due to hereditary angioedema

Jerome Adams on the need for new antivirals for Covid

HIV drugs protect against transmission, even in unprotected sex

As demand for Covid shots wanes, Moderna seeks its next success

Scientists successfully use ultrasound imaging to map brain activity

explore

Kaiser's Risant Health gobbled up Geisinger. Who is next?

At ASCO, AstraZeneca reports strong data for breast cancer drug

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Focused ultrasound for uterine fibroids: an uphill battle

focus

entertainment

entertainment

Wikipedia